Screener / SEC EDGAR /CIK 0001865782 /10-K filed Feb 27, 2026, compared with Mar 6, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

BrightSpring Health Services, Inc. BTSG

Compare with peers Embed
Earnings releases

Latest results release: Oct 30, 2026

8-K item 2.02, exhibit 99

What BTSG's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

Management also defines Adjusted EPS as Diluted EPS, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, and the income tax impact of the aforementioned adjustments. release Oct 30, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 30, 2026 · EX-99.1

BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results

Open on SEC

BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance LOUISVILLE, Ky., October 30, 2026 — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2026, and increased full year 2026 Revenue and Adjusted EBITDA 1 guidance. Third Quarter 2026 Financial Highlights (note: On March 30, 2026, BrightSpring completed the divestiture of the Community Living business and, as such, all financial results provided pertain to continuing operations) • Net revenue of $4,213 million, up 26.4% compared to $3,334 million in the third quarter of 2025 • Gross profit of $519 million, up 32.3% compared to $392 million in the third quarter of 2025 • Net income from continuing operations of $101 million compared to $38 million in the third quarter of 2025 • Adjusted EBITDA 1 of $228 million, up 42.0% compared to $160 million in the third quarter of 2025 • Leverage of 1.79x as of September 30, 2026, compared to leverage of 2.15x on June 30, 2026 "Our third quarter results again reflect the commitment of our team to patient care and operational execution across our Pharmacy and Provider businesses," said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring. "We have a differentiated company, our value proposition for healthcare stakeholders is clear, and our confidence in the future remains high, supported by a broad set of process and growth drivers across a uniquely scaled and high-quality platform. As we progress through 2026, we believe that BrightSpring is well -positioned to make a greater and greater impact and deliver durable growth in 2027 and beyond." 1 Adjusted EBITDA is a non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the end of this press release for a reconciliation of Adjusted EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP. Key Financials 2

1 Adjusted EBITDA and Segment EBITDA are non-GAAP financial measures. Please see “Non-GAAP Financial Information” and the end of this press release for a reconciliation of Adjusted EBITDA and Segment EBITDA to net income from continuing operations, the most directly comparable financial measure prepared in accordance with GAAP. 2 Financial tables may not foot due to rounding. 3 Effective July 1, 2026, the Company realigned its Rehab in Motion business from the Rehab Care sub-segment to the Home Health Care sub-segment to reflect how the business is managed. Prior period sub-segment information has been recast to conform to the current presentation. The change did not affect consolidated company or segment results. The impact on prior periods was not material. 2

For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living business:

Pharmacy Segment Revenue of $14,000 million to $14,200 million, or 22.3% to 24.1% growth

Provider Segment Revenue of $1,900 million to $1,925 million, or 29.7% to 31.4% growth

Total Adjusted EBITDA 3 of $850 million to $860 million, or 37.6% to 39.3% growth

The Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026

3A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income from continuing operations cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

The Company will host a conference call today, October 30that 8:30 a.m. Eastern Time. Investors interested in listening to the conference call are required toregister online.

A live and archived webcast of the event will be available on the “Events & Presentations” section of the BrightSpring website athttps://ir.brightspringhealth.com/. The Company has posted supplemental information on the third quarter 2026 results that it will reference during the conference call. The supplemental information can be found under the “Events & Presentations” on the Company’s investor relations page.

BrightSpring Health Services provides complementary home- and community-based health solutions for medically complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care, and rehabilitation, we provide comprehensive and more integrated care and clinical solutions in all 50 states to approximately 500,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and industry-leading quality metrics across its services lines, while improving the health and quality of life for high-need individuals and reducing overall healthcare system costs.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating

The forward-looking statements are based on management’s current expectations and are not historical facts or guarantees of future performance. The forward- looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

our inability to maintain relationships with existing patient referral sources or establish new referral sources;

changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;

cost containment initiatives of third-party payors, including post-payment audits;

the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;

changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;

our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;

changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;

changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;

reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;

compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;

limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;

delays in collection or non-collection of our accounts receivable, particularly during the business integration process;

failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;

our ability to identify, successfully complete and manage acquisitions, joint ventures, divestitures and other significant transactions and strategic initiatives;

maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;

contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;

effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;

security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;

various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;

our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;

factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;

inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;

the significant interests of KKR Stockholder may conflict with our stockholders’

significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and

The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.

For additional information on these and other factors that could cause BrightSpring’s actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website atwww.sec.gov.

This press release contains “non-GAAP financial measures,” including “EBITDA,” “Segment EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.

Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS are non-GAAP measures of our financial performance and should not be considered as an alternative to net income as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.

Management defines EBITDA as net income from continuing operations before income tax expense, interest expense, net and depreciation and amortization. Management defines Segment EBITDA as segment operating income before income tax expense, interest expense, net and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, and restructuring and divestiture-related and other costs. Management also defines Adjusted EPS as Diluted EPS, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, and the income tax impact of the aforementioned adjustments.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.

7 BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated Balance Sheets September 30, 2026 and December 31, 2025 (In thousands, except share and per share data) (Unaudited)

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash $ 717,840 $ 88,370 equivalents Accounts receivable, net of allowance 1,216,377 989,719 for credit losses Inventories 671,590 815,180 Prepaid expenses and other current 159,950 118,592 assets Current assets held for — 882,189 sale Total current assets 2,765,757 2,894,050 Property and equipment, net of accumulated depreciation of $419,016 and $404,878 at 213,530 204,689 September 30, 2026 and December 31, 2025, respectively Goodwill 2,537,128 2,545,673 Intangible assets, net of accumulated 491,661 557,555 amortization Operating lease 169,977 171,632 right-of-use assets, net Other assets 88,568 39,712 Total assets $ 6,266,621 $ 6,413,311 Liabilities, Redeemable Noncontrolling Interests, and Equity Current liabilities: Trade accounts payable $ 1,232,288 $ 1,217,946 Accrued expenses 390,967 333,024 Current portion of obligations under 46,296 42,936 operating leases Current portion of obligations under 5,988 6,794 financing leases Current portion of 35,277 52,340 long-term debt Current liabilities held — 195,994 for sale Total current 1,710,816 1,849,034 liabilities Obligations under operating leases, net 133,569 135,420 of current portion Obligations under financing leases, net 11,072 14,544 of current portion Long-term debt, net of 2,146,779 2,455,204 current portion Deferred income taxes, 10,336 6,178 net Long-term liabilities 68,234 66,565 Total liabilities 4,080,806 4,526,945 Redeemable 9,200 11,227 noncontrolling interests Shareholders’ equity: Common stock, $0.01 par value, 1,500,000,000 shares authorized, 198,814,320 and 192,124,125 shares $ 1,988 $ 1,921 issued and outstanding at September 30, 2026 and December 31, 2025 respectively Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and — — outstanding at September 30, 2026 and December 31, 2025 Additional paid-in 2,021,881 1,954,482 capital Retained earnings 138,572 (74,647 ) (accumulated deficit) Accumulated other comprehensive income 14,099 (6,691 ) (loss) Total shareholders’ 2,176,540 1,875,065 equity Noncontrolling interest 75 74 Total equity 2,176,615 1,875,139 Total liabilities, redeemable $ 6,266,621 $ 6,413,311 noncontrolling interests, and equity

BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated Statements of Operations For the three and nine months ended September 30, 2026 and 2025 (In thousands, except per share amounts) (Unaudited)

BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated Statements of Cash Flows For the three and nine months ended September 30, 2026 and 2025 (In thousands) (Unaudited)

BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Segment EBITDA For the three and nine months ended September 30, 2026 and 2025 (Unaudited) The following table reconciles net income from continuing operations to Segment EBITDA:

BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of EBITDA and Adjusted EBITDA For the three and nine months ended September 30, 2026 and 2025 (Unaudited) The following table reconciles net income from continuing operations to EBITDA and Adjusted EBITDA:

(1) Represents non-cash share-based compensation to certain members of our management and full-time employees. (2) Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. (3) Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures.

BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Adjusted EPS For the three and nine months ended September 30, 2026 and 2025 (Unaudited) The following table reconciles diluted EPS to Adjusted EPS:

(1) This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA. (2) The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non- GAAP adjustment. For all periods presented, the income tax impact on adjustments is inclusive of a discrete tax benefit related to share-based compensation.

Full text with the tables
BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results
and Increases Full Year 2026 Guidance LOUISVILLE, Ky., October 30, 2026 —
BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ:
BTSG), a leading provider of home- and community-based health services for
complex populations, today announced financial results for the third quarter
ended September 30, 2026, and increased full year 2026 Revenue and Adjusted
EBITDA 1 guidance. Third Quarter 2026 Financial Highlights (note: On March 30,
2026, BrightSpring completed the divestiture of the Community Living business
and, as such, all financial results provided pertain to continuing operations) •
Net revenue of $4,213 million, up 26.4% compared to $3,334 million in the third
quarter of 2025 • Gross profit of $519 million, up 32.3% compared to $392
million in the third quarter of 2025 • Net income from continuing operations of
$101 million compared to $38 million in the third quarter of 2025 • Adjusted
EBITDA 1 of $228 million, up 42.0% compared to $160 million in the third quarter
of 2025 • Leverage of 1.79x as of September 30, 2026, compared to leverage of
2.15x on June 30, 2026 "Our third quarter results again reflect the commitment
of our team to patient care and operational execution across our Pharmacy and
Provider businesses," said Jon Rousseau, Chairman, President, and Chief
Executive Officer of BrightSpring. "We have a differentiated company, our value
proposition for healthcare stakeholders is clear, and our confidence in the
future remains high, supported by a broad set of process and growth drivers
across a uniquely scaled and high-quality platform. As we progress through 2026,
we believe that BrightSpring is well -positioned to make a greater and greater
impact and deliver durable growth in 2027 and beyond." 1 Adjusted EBITDA is a
non-GAAP financial measure. Please see “Non-GAAP Financial Information” at the
end of this press release for a reconciliation of Adjusted EBITDA to net income
from continuing operations, the most directly comparable financial measure
prepared in accordance with GAAP. Key Financials 2
                                                                                
                  Three                               Nine                      
                 Months                             Months                      
                  Ended                              Ended                      
              September                          September                      
                    30,                                30,                      
             (Unaudite…                         (Unaudite…                      
                   2026          2025    %            2026         2025    %    
  ($ in                                                                         
  millions)                                                                     
  Pharmacy            $                                                         
  Solutions       3,732     $   2,967    26%     $  10,311     $  8,289    24%  
  Revenue                                                                       
  Provider                                                                      
  Services          481           367    31%         1,389        1,071    30%  
  Revenue                                                                       
  Total               $    $    3,334    26%    $   11,700    $   9,360    25%  
  Revenue         4,213                                                         
                                                                                
1                                                                               
                                                                                
                 Three                               Nine                       
                Months                             Months                       
                 Ended                              Ended                       
             September                          September                       
                   30,                                30,                       
            (Unaudite…                         (Unaudite…                       
                  2026         2025    %             2026         2025    %     
  ($ in                                                                         
  million…                                                                      
  Pharmacy                                                                      
  Solutio…  $      202            $    43%     $      551            $    45%   
  Segment                       141                                381          
  EBITDA                                                                        
  Provider                                                                      
  Services          79           61    30%            220          168    31%   
  Segment                                                                       
  EBITDA                                                                        
  Total                           $                                  $          
  Segment   $      281          202    39%     $      771          550    40%   
  EBITDA(…                                                                      
  Corpora…         -53          -41    n.m.          -148         -116    n.m.  
  Costs                                                                         
  Total                                                                         
  Company   $      228            $    42%     $      623            $    44%   
  Adjusted                      160                                434          
  EBITDA(…                                                                      
                                                                                
*n.m.: not meaningful Business Metrics
                                                                                
                  Three                               Nine                      
                 Months                             Months                      
                  Ended                              Ended                      
              September                          September                      
                    30,                                30,                      
             (Unaudite…                         (Unaudite…                      
                   2026          2025    %            2026         2025    %    
  Pharmacy                                                                      
  Solutions                                                                     
  Prescrip…  10,949,875    10,793,219    2%     32,523,789    32,522,2…    0%   
  dispensed                                                                     
  Revenue                                                                       
  per            340.86        274.89    24%        317.03       254.88    24%  
  script                                                                        
  ($)                                                                           
  Gross                                                                         
  Profit                                                                        
  per             28.86         22.76    27%         28.13        21.01    34%  
  script                                                                        
  ($)                                                                           
  Provider                                                                      
  Services                                                                      
  Home                                                                          
  Health                                                                        
  Care           47,256        29,980    58%        46,898       30,212    55%  
  average                                                                       
  daily                                                                         
  census(3)                                                                     
  Rehab                                                                         
  Care            7,574         6,932    9%          7,345        6,806    8%   
  persons                                                                       
  served(3)                                                                     
  Personal                                                                      
  Care           16,320        16,134    1%         16,253       16,046    1%   
  persons                                                                       
  served                                                                        
                                                                                
1 Adjusted EBITDA and Segment EBITDA are non-GAAP financial measures. Please see
“Non-GAAP Financial Information” and the end of this press release for a
reconciliation of Adjusted EBITDA and Segment EBITDA to net income from
continuing operations, the most directly comparable financial measure prepared
in accordance with GAAP. 2 Financial tables may not foot due to rounding. 3
Effective July 1, 2026, the Company realigned its Rehab in Motion business from
the Rehab Care sub-segment to the Home Health Care sub-segment to reflect how
the business is managed. Prior period sub-segment information has been recast to
conform to the current presentation. The change did not affect consolidated
company or segment results. The impact on prior periods was not material.
2                                                                               
                                                                                
Full Year 2026 Financial Guidance                                               
                                                                                
For the full year 2026, BrightSpring is increasing Revenue and Adjusted EBITDA  
guidance, which excludes the Community Living business and the effects of any   
future closed acquisitions. All growth rates are shown as compared to the full  
year 2025 Revenue and Adjusted EBITDA results, excluding the Community Living   
business:                                                                       
                                                                                
Revenues of $15,900 million to $16,125 million, or 23.2% to 24.9% growth        
                                                                                
Pharmacy Segment Revenue of $14,000 million to $14,200 million, or 22.3% to     
24.1% growth                                                                    
                                                                                
Provider Segment Revenue of $1,900 million to $1,925 million, or 29.7% to 31.4% 
growth                                                                          
                                                                                
Total Adjusted EBITDA 3 of $850 million to $860 million, or 37.6% to 39.3%      
growth                                                                          
                                                                                
The Amedisys and LHC branches acquisition is expected to contribute             
approximately $35 million in Adjusted EBITDA in 2026                            
                                                                                
3A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted 
EBITDA to GAAP net income from continuing operations cannot be provided without 
unreasonable effort because of the inherent difficulty of accurately forecasting
the occurrence and financial impact of the various adjusting items necessary for
such reconciliation that have not yet occurred, are out of our control, or      
cannot be reasonably predicted. For the same reasons, the Company is unable to  
assess the probable significance of the unavailable information, which could    
have a material impact on its future GAAP financial results.                    
                                                                                
Webcast and Conference Call Details                                             
                                                                                
The Company will host a conference call today, October 30that 8:30 a.m. Eastern 
Time. Investors interested in listening to the conference call are required     
toregister online.                                                              
                                                                                
A live and archived webcast of the event will be available on the “Events &     
Presentations” section of the BrightSpring website                              
athttps://ir.brightspringhealth.com/. The Company has posted supplemental       
information on the third quarter 2026 results that it will reference during the 
conference call. The supplemental information can be found under the “Events &  
Presentations” on the Company’s investor relations page.                        
                                                                                
About BrightSpring Health Services                                              
                                                                                
BrightSpring Health Services provides complementary home- and community-based   
health solutions for medically complex populations in need of specialized and/or
chronic care. Through the Company’s service lines, including pharmacy, home     
health care, and rehabilitation, we provide comprehensive and more integrated   
care and clinical solutions in all 50 states to approximately 500,000 customers,
clients and patients daily. BrightSpring has consistently demonstrated strong   
and industry-leading quality metrics across its services lines, while improving 
the health and quality of life for high-need individuals and reducing overall   
healthcare system costs.                                                        
                                                                                
Forward-Looking Statements                                                      
                                                                                
This press release contains “forward-looking statements” within the meaning of  
the Private Securities Litigation Reform Act of 1995. These forward-looking     
statements reflect our current views with respect to, among other things, our   
operations and financial performance. Forward-looking statements include all    
statements that are not historical facts. These forward-looking statements may  
relate to matters which include, but are not limited to, industries, business   
strategy, goals and expectations concerning our market position, future         
operations, margins, profitability, capital expenditures, liquidity and capital 
resources and other financial and operating                                     
                                                                                
3                                                                               
                                                                                
information. In some cases, we have used words such as “anticipate,” “assume,”  
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”  
“potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,”     
“target,” “guidance,” the negative version of these words, or similar terms and 
phrases to identify these forward-looking statements.                           
                                                                                
The forward-looking statements are based on management’s current expectations   
and are not historical facts or guarantees of future performance. The forward-  
looking statements relate to the future and are therefore subject to various    
risks, uncertainties, assumptions, or changes in circumstances that are         
difficult to predict or quantify. Our expectations, beliefs, and projections are
expressed in good faith and we believe there is a reasonable basis for them.    
However, there can be no assurance that management’s expectations, beliefs, and 
projections will result or be achieved. Actual results may differ materially    
from these expectations due to changes in global, regional, or local economic,  
business, competitive, market, regulatory, and other factors, many of which are 
beyond our control. We believe that these factors include but are not limited to
the following:                                                                  
                                                                                
our operation in a highly competitive industry;                                 
                                                                                
our inability to maintain relationships with existing patient referral sources  
or establish new referral sources;                                              
                                                                                
changes to Medicare and Medicaid rates or methods governing Medicare and        
Medicaid payments for our services;                                             
                                                                                
cost containment initiatives of third-party payors, including post-payment      
audits;                                                                         
                                                                                
the implementation of alternative payment models and the transition of Medicaid 
and Medicare beneficiaries to managed care organizations may limit our market   
share and could adversely affect our revenues;                                  
                                                                                
changes in the case mix of patients, as well as payor mix and payment           
methodologies, and decisions and operations of third-party organizations;       
                                                                                
our reliance on federal and state spending, budget decisions, and continuous    
governmental operations which may fluctuate under different political           
conditions;                                                                     
                                                                                
changes in drug utilization and/or pricing, PBM contracts, and Medicare Part    
D/Medicaid reimbursement, which may negatively impact our profitability;        
                                                                                
changes in our relationships with pharmaceutical suppliers, including changes in
drug availability or pricing;                                                   
                                                                                
reliance on the continual recruitment and retention of nurses, pharmacists,     
therapists, caregivers, direct support professionals, and other qualified       
personnel, including senior management;                                         
                                                                                
compliance with or changes to federal, state, and local laws and regulations    
that govern our employment practices, including minimum wage, living wage, and  
paid time-off requirements;                                                     
                                                                                
fluctuation of our results of operations on a quarterly basis;                  
                                                                                
harm caused by labor relation matters;                                          
                                                                                
limitations in our ability to control reimbursement rates received for our      
services if we are unable to maintain or reduce our costs to provide such       
services;                                                                       
                                                                                
delays in collection or non-collection of our accounts receivable, particularly 
during the business integration process;                                        
                                                                                
failure to manage our growth effectively, which may inhibit our ability to      
execute our business plan, maintain high levels of service and satisfaction or  
adequately address competitive challenges;                                      
                                                                                
our ability to identify, successfully complete and manage acquisitions, joint   
ventures, divestitures and other significant transactions and strategic         
initiatives;                                                                    
                                                                                
our ability to continue to provide consistently high quality of care;           
                                                                                
4                                                                               
                                                                                
maintenance of our corporate reputation or the emergence of adverse publicity,  
including negative information on social media or changes in public perception  
of our services;                                                                
                                                                                
contract continuance, expansion and renewal with our existing customers,        
including renewals at lower fee levels, customers declining to purchase         
additional services from us, or reduction in the services received from us      
pursuant to those contracts;                                                    
                                                                                
effective investment in, implementation of improvements to and proper           
maintenance of the uninterrupted operation and data integrity of our information
technology and other business systems;                                          
                                                                                
security breaches, loss of data, and other disruptions, which could compromise  
sensitive business or patient information; cause a loss of confidential patient 
data, employee data or personal information; or prevent access to critical      
information and thereby expose us to liability, litigation, and federal and     
state governmental inquiries and damage our reputation and brand;               
                                                                                
risks related to credit card payments and other payment methods;                
                                                                                
potential substantial malpractice or other similar claims;                      
                                                                                
various risks related to governmental inquiries, regulatory actions, and        
whistleblower and other lawsuits, which may not be entirely covered by          
insurance;                                                                      
                                                                                
our current insurance program, which may expose us to unexpected costs,         
particularly if we incur losses not covered by our insurance or if claims or    
losses differ from our estimates;                                               
                                                                                
factors outside of our control, including those listed, which have required and 
could in the future require us to record an asset impairment of goodwill;       
                                                                                
a pandemic, epidemic, or outbreak of an infectious disease;                     
                                                                                
inclement weather, natural disasters, acts of terrorism, riots, civil           
insurrection or social unrest, looting, protests, strikes, or street            
demonstrations;                                                                 
                                                                                
our inability to adequately protect our intellectual property rights;           
                                                                                
risks related to our compliance with our regulatory framework;                  
                                                                                
the significant interests of KKR Stockholder may conflict with our stockholders’
interests in the future;                                                        
                                                                                
our substantial indebtedness;                                                   
                                                                                
significant changes in tax or trade policies, tariffs, or trade relations       
between the United States and other countries, such as the imposition of        
unilateral tariffs on imported products, including impacts on imported drug     
products, which could result in supply chain disruptions and significant        
increases in costs; and                                                         
                                                                                
fluctuations in the amount and frequency of repurchases of our common stock.    
                                                                                
The forward-looking statements included in this press release are made only as  
of the date of this press release, and we undertake no obligation to publicly   
update or revise any forward-looking statement, whether as a result of new      
information, future developments, or otherwise, except as required by law. These
factors should not be construed as exhaustive, and should one or more of these  
risks or uncertainties materialize, or should any of our assumptions prove      
incorrect, our actual results may vary in material respects from those projected
in these forward-looking statements. Factors or events that could cause our     
actual results to differ may emerge from time to time, and it is not possible   
for us to predict all of them. We may not actually achieve the plans,           
intentions, or expectations disclosed in our forward-looking statements and you 
should not place undue reliance on our forward-looking statements. Our forward- 
looking statements do not reflect the potential impact of any future            
acquisitions, mergers, dispositions, joint ventures, investments, or other      
strategic transactions we may make.                                             
                                                                                
For additional information on these and other factors that could cause          
BrightSpring’s actual results to differ materially from expected results, please
see our filings with the Securities and Exchange Commission (the “SEC”), which  
are accessible on the SEC’s website atwww.sec.gov.                              
                                                                                
5                                                                               
                                                                                
Non-GAAP Financial Measures                                                     
                                                                                
This press release contains “non-GAAP financial measures,” including “EBITDA,”  
“Segment EBITDA,” “Adjusted EBITDA,” and “Adjusted EPS,” which are financial    
measures that either exclude or include amounts that are not excluded or        
included in the most directly comparable measures calculated and presented in   
accordance with accounting principles generally accepted in the United States,  
or GAAP.                                                                        
                                                                                
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in
this release as supplemental measures of financial performance that are not     
required by, or presented in accordance with, GAAP, because we believe they     
assist investors and analysts in comparing our operating performance across     
reporting periods on a consistent basis by excluding items that we do not       
believe are indicative of our core operating performance. Management also       
believes that these measures are useful to investors in highlighting trends in  
our operating performance, while other measures can differ significantly        
depending on long-term strategic decisions regarding capital structure, the tax 
jurisdictions in which we operate and capital investments. Management uses      
EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP    
measures of performance in the evaluation of the effectiveness of our business  
strategies, to make budgeting decisions, to establish and award discretionary   
annual incentive compensation, and to compare our performance against that of   
other peer companies using similar measures.                                    
                                                                                
Management supplements GAAP results with non-GAAP financial measures to provide 
a more complete understanding of the factors and trends affecting the business  
than GAAP results alone. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted  
EPS are non-GAAP measures of our financial performance and should not be        
considered as an alternative to net income as a measure of financial performance
or any other performance measures derived in accordance with GAAP. Additionally,
these measures are not intended to be a measure of free cash flow available for 
management’s discretionary use as they do not consider certain cash requirements
such as tax payments, debt service requirements, total capital expenditures, and
certain other cash costs that may recur in the future.                          
                                                                                
Management defines EBITDA as net income from continuing operations before income
tax expense, interest expense, net and depreciation and amortization. Management
defines Segment EBITDA as segment operating income before income tax expense,   
interest expense, net and depreciation and amortization. Management also defines
Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based     
compensation, acquisition, integration and transaction-related costs, and       
restructuring and divestiture-related and other costs. Management also defines  
Adjusted EPS as Diluted EPS, further adjusted to exclude non-cash share-based   
compensation, acquisition, integration and transaction-related costs,           
restructuring and divestiture-related and other costs, and the income tax impact
of the aforementioned adjustments.                                              
                                                                                
The presentations of these measures have limitations as analytical tools and    
should not be considered in isolation, or as a substitute for analysis of our   
results as reported under GAAP. Because not all companies use identical         
calculations, the presentations of these measures may not be comparable to other
similarly titled measures of other companies and can differ significantly from  
company to company. Please see the end of this press release for reconciliations
of non-GAAP financial measures to the most directly comparable financial measure
prepared in accordance with GAAP.                                               
                                                                                
6                                                                               
                                                                                
BrightSpring Contact:                                                           
                                                                                
Investor Relations:                                                             
                                                                                
David Deuchler, CFA                                                             
                                                                                
SVP, Strategic Finance & Investor Relations                                     
                                                                                
Executive Director, BrightSpring Health Foundation                              
                                                                                
[email protected]                                                       
                                                                                
917.209.5605                                                                    
                                                                                
Media Contact:Leigh White                                                       
Vice President, Communications & PR                                             
                                                                                
[email protected]                                              
                                                                                
502.630.7412                                                                    
                                                                                
7                                                                               
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated
Balance Sheets September 30, 2026 and December 31, 2025 (In thousands, except
share and per share data) (Unaudited)
                                                                                
                                 September 30, 2026       December 31, 2025     
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash               $             717,840    $             88,370     
  equivalents                                                                   
  Accounts receivable, net                                                      
  of allowance                            1,216,377                 989,719     
  for credit losses                                                             
  Inventories                               671,590                 815,180     
  Prepaid expenses and                                                          
  other current                             159,950                 118,592     
  assets                                                                        
  Current assets held for                         —                 882,189     
  sale                                                                          
  Total current assets                    2,765,757               2,894,050     
  Property and equipment,                                                       
  net of accumulated                                                            
  depreciation of $419,016                                                      
  and $404,878 at                           213,530                 204,689     
  September 30, 2026 and                                                        
  December 31, 2025,                                                            
  respectively                                                                  
  Goodwill                                2,537,128               2,545,673     
  Intangible assets, net                                                        
  of accumulated                            491,661                 557,555     
  amortization                                                                  
  Operating lease                           169,977                 171,632     
  right-of-use assets, net                                                      
  Other assets                               88,568                  39,712     
  Total assets                $           6,266,621    $          6,413,311     
  Liabilities, Redeemable                                                       
  Noncontrolling                                                                
  Interests, and Equity                                                         
  Current liabilities:                                                          
  Trade accounts payable      $           1,232,288    $          1,217,946     
  Accrued expenses                          390,967                 333,024     
  Current portion of                                                            
  obligations under                          46,296                  42,936     
  operating leases                                                              
  Current portion of                                                            
  obligations under                           5,988                   6,794     
  financing leases                                                              
  Current portion of                         35,277                  52,340     
  long-term debt                                                                
  Current liabilities held                        —                 195,994     
  for sale                                                                      
  Total current                           1,710,816               1,849,034     
  liabilities                                                                   
  Obligations under                                                             
  operating leases, net                     133,569                 135,420     
  of current portion                                                            
  Obligations under                                                             
  financing leases, net                      11,072                  14,544     
  of current portion                                                            
  Long-term debt, net of                  2,146,779               2,455,204     
  current portion                                                               
  Deferred income taxes,                     10,336                   6,178     
  net                                                                           
  Long-term liabilities                      68,234                  66,565     
  Total liabilities                       4,080,806               4,526,945     
  Redeemable                                  9,200                  11,227     
  noncontrolling interests                                                      
  Shareholders’ equity:                                                         
  Common stock, $0.01 par                                                       
  value, 1,500,000,000                                                          
  shares authorized,                                                            
  198,814,320 and                                                               
  192,124,125 shares          $               1,988    $              1,921     
  issued and outstanding                                                        
  at September 30, 2026                                                         
  and December 31,    2025                                                      
  respectively                                                                  
  Preferred stock, $0.01                                                        
  par value, 250,000,000                                                        
  authorized, no shares                                                         
  issued and                                      —                       —     
  outstanding at September                                                      
  30, 2026 and December                                                         
  31, 2025                                                                      
  Additional paid-in                      2,021,881               1,954,482     
  capital                                                                       
  Retained earnings                         138,572                 (74,647  )  
  (accumulated deficit)                                                         
  Accumulated other                                                             
  comprehensive income                       14,099                  (6,691  )  
  (loss)                                                                        
  Total shareholders’                     2,176,540               1,875,065     
  equity                                                                        
  Noncontrolling interest                        75                      74     
  Total equity                            2,176,615               1,875,139     
  Total liabilities,                                                            
  redeemable                  $           6,266,621    $          6,413,311     
  noncontrolling                                                                
  interests, and equity                                                         
                                                                                
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated
Statements of Operations For the three and nine months ended September 30, 2026
and 2025 (In thousands, except per share amounts) (Unaudited)
                                                                                
          For                                  For                              
          the                                  the                              
          Three                                Nine                             
          Mont…                                Mon…                             
          Ended                                End…                             
          Sept…                                Sep…                             
          30,                                  30,                              
  Rev…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Pro…    $      3,73…       $     2,96…       $     10,3…       $     8,2…     
  Ser…           480,…             367,…             1,38…             1,0…     
  Tot…           4,21…             3,33…             11,7…             9,3…     
  rev…                                                                          
  Cost                                                                          
  of             3,41…             2,72…             9,39…             7,6…     
  goo…                                                                          
  Cost                                                                          
  of             278,…             220,…             810,…             648…     
  ser…                                                                          
  Gro…           518,…             392,…             1,49…             1,1…     
  pro…                                                                          
  Sel…                                                                          
  gen…                                                                          
  and            358,…             304,…             1,08…             918…     
  adm…                                                                          
  exp…                                                                          
  Ope…           160,…             87,8…             412,…             187…     
  inc…                                                                          
  Int…                                                                          
  exp…           31,0…             38,2…             106,…             118…     
  net                                                                           
  Inc…                                                                          
  from                                                                          
  con…                                                                          
  ope…           129,…             49,6…             305,…             68,…     
  bef…                                                                          
  inc…                                                                          
  tax…                                                                          
  Inc…                                                                          
  tax            28,6…             12,1…             44,0…             13,…     
  exp…                                                                          
  Inc…                                                                          
  from                                                                          
  con…                                                                          
  ope…           100,…             37,4…             261,…             55,…     
  net                                                                           
  of                                                                            
  inc…                                                                          
  tax…                                                                          
  (Lo…                                                                          
  inc…                                                                          
  from                                                                          
  dis…                                                                          
  ope…            (503  )          17,7…             71,4…             56,…     
  net                                                                           
  of                                                                            
  inc…                                                                          
  tax…                                                                          
  Net            100,…             55,2…             333,…             111…     
  inc…                                                                          
  Net                                                                           
  inc…                                                                          
  (lo…                                                                          
  att…                                                                          
  to                                                                            
  non…             161              (595  )            (77  )          (1,…  )  
  int…                                                                          
  inc…                                                                          
  in                                                                            
  con…                                                                          
  ope…                                                                          
  Net                                                                           
  inc…                                                                          
  att…                                                                          
  to                                                                            
  Bri…    $      100,…       $     55,8…       $     333,…       $     113…     
  Hea…                                                                          
  Ser…                                                                          
  Inc.                                                                          
  and                                                                           
  sub…                                                                          
  Net                                                                           
  inc…                                                                          
  per                                                                           
  com…                                                                          
  sha…                                                                          
  Bas…                                                                          
  inc…                                                                          
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  att…                                                                          
  to                                                                            
  com…                                                                          
  sha…                                                                          
  Con…    $       0.49       $      0.19       $      1.27       $     0.28     
  ope…                                                                          
  Dis…    $      (0.01  )    $      0.08       $      0.35       $     0.28     
  ope…                                                                          
  Net                                                                           
  inc…    $       0.48       $      0.27       $      1.62       $     0.56     
  per                                                                           
  sha…                                                                          
  Dil…                                                                          
  inc…                                                                          
  (lo…                                                                          
  per                                                                           
  sha…                                                                          
  att…                                                                          
  to                                                                            
  com…                                                                          
  sha…                                                                          
  Con…    $       0.46       $      0.17       $      1.18       $     0.26     
  ope…                                                                          
  Dis…    $      (0.01  )    $      0.09       $      0.33       $     0.26     
  ope…                                                                          
  Net                                                                           
  inc…    $       0.45       $      0.26       $      1.51       $     0.52     
  per                                                                           
  sha…                                                                          
  Wei…                                                                          
  ave…                                                                          
  sha…                                                                          
  out…                                                                          
  Bas…           207,…             203,…             205,…             202…     
  Dil…           220,…             217,…             220,…             218…     
                                                                                
BrightSpring Health Services, Inc. and Subsidiaries Condensed Consolidated
Statements of Cash Flows For the three and nine months ended September 30, 2026
and 2025 (In thousands) (Unaudited)
                                                                                
          For                                  For                              
          the                                  the                              
          Three                                Nine                             
          Mont…                                Mon…                             
          Ended                                End…                             
          Sept…                                Sep…                             
  Ope…    30,                                  30,                              
  act…    2026               2025              2026              2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Net     $      100,…       $     55,2…       $     333,…       $     111…     
  inc…                                                                          
  Adj…                                                                          
  to                                                                            
  rec…                                                                          
  net                                                                           
  inc…                                                                          
  to                                                                            
  net                                                                           
  cash                                                                          
  pro…                                                                          
  by                                                                            
  ope…                                                                          
  act…                                                                          
  Dep…                                                                          
  and            38,3…             40,7…             118,…             124…     
  amo…                                                                          
  Imp…                                                                          
  of             5,195             2,507             8,240             6,5…     
  lon…                                                                          
  ass…                                                                          
  Cha…                                                                          
  in                                                                            
  fair                                                                          
  val…               —             (3,2…  )              —             (1,…  )  
  of                                                                            
  con…                                                                          
  con…                                                                          
  net                                                                           
  Pay…                                                                          
  of                                                                            
  con…                                                                          
  con…                                                                          
  in                                                                            
  exc…               —             (4,6…  )              —             (6,…  )  
  of                                                                            
  acq…                                                                          
  date                                                                          
  fair                                                                          
  val…                                                                          
  Pro…                                                                          
  for            5,829             8,065             28,6…             48,…     
  cre…                                                                          
  los…                                                                          
  Amo…                                                                          
  of                                                                            
  def…           2,553             2,841             8,317             8,3…     
  debt                                                                          
  iss…                                                                          
  cos…                                                                          
  Sha…           17,8…             17,2…             41,0…             55,…     
  com…                                                                          
  Def…                                                                          
  inc…           6,484             14,3…             (3,0…  )          18,…     
  tax…                                                                          
  net                                                                           
  Loss                                                                          
  (ga…                                                                          
  on                                                                            
  sale              23                 —             (101…  )             —     
  of                                                                            
  dis…                                                                          
  ope…                                                                          
  Oth…            (771  )            (74  )            243             (335  )  
  Cha…                                                                          
  in                                                                            
  ope…                                                                          
  ass…                                                                          
  and                                                                           
  lia…                                                                          
  net                                                                           
  of                                                                            
  acq…                                                                          
  and                                                                           
  dis…                                                                          
                                                                                
  Acc…           (83,…  )          (49,…  )          (235…  )          (16…  )  
  rec…                                                                          
  Pre…                                                                          
  exp…                                                                          
  and            45,0…               446             (41,…  )          24,…     
  oth…                                                                          
  cur…                                                                          
  ass…                                                                          
  Inv…           (96,…  )          (13,…  )          143,…             (2,…  )  
  Tra…                                                                          
  acc…           142,…             (10,…  )          54,9…             42,…     
  pay…                                                                          
  Acc…           19,2…             60,7…             47,1…             17,…     
  exp…                                                                          
  Oth…                                                                          
  ass…           1,687             (12,…  )          (30,…  )          (27…  )  
  and                                                                           
  lia…                                                                          
  Net                                                                           
  cash                                                                          
  pro…    $      204,…       $     107,…       $     371,…       $     258…     
  by                                                                            
  ope…                                                                          
  act…                                                                          
  Inv…                                                                          
  act…                                                                          
  Pur…                                                                          
  of                                                                            
  pro…    $      (22,…  )    $     (15,…  )    $     (72,…  )    $     (57…  )  
  and                                                                           
  equ…                                                                          
  Acq…                                                                          
  of             (1,9…  )          (1,5…  )          (44,…  )          (8,…  )  
  bus…                                                                          
  Pro…                                                                          
  from                                                                          
  sale               —                 —             810,…                —     
  of                                                                            
  dis…                                                                          
  ope…                                                                          
  Oth…             827             (6,4…  )          1,893             (5,…  )  
  Net                                                                           
  cash                                                                          
  (us…                                                                          
  in)     $      (23,…  )    $     (23,…  )    $     696,…       $     (71…  )  
  pro…                                                                          
  by                                                                            
  inv…                                                                          
  act…                                                                          
  Fin…                                                                          
  act…                                                                          
  Lon…                                                                          
  debt           (11,…  )          (14,…  )    $     (332…  )    $     (37…  )  
  rep…                                                                          
  Rep…                                                                          
  of                                                                            
  the                                                                           
  Rev…               —                 —                 —             (63…  )  
  Cre…                                                                          
  Fac…                                                                          
  net                                                                           
  Pay…                                                                          
  of                                                                            
  debt               —                 —             (3,3…  )             —     
  iss…                                                                          
  cos…                                                                          
  Rep…                                                                          
  of                                                                            
  sha…               —                 —             (120…  )             —     
  of                                                                            
  com…                                                                          
  sto…                                                                          
  Pro…                                                                          
  from                                                                          
  sha…                                                                          
  iss…           4,841             5,619             37,2…             14,…     
  und…                                                                          
  sha…                                                                          
  com…                                                                          
  plan                                                                          
  Tax…                                                                          
  paid                                                                          
  rel…                                                                          
  to                                                                            
  net            (4,9…  )          (1,0…  )          (11,…  )          (5,…  )  
  sha…                                                                          
  set…                                                                          
  of                                                                            
  equ…                                                                          
  awa…                                                                          
  Pur…                                                                          
  of                                                                            
  red…               —                 —              (267  )          (5,…  )  
  non…                                                                          
  int…                                                                          
  Pay…                                                                          
  of                                                                            
  fin…           (1,7…  )          (3,4…  )          (7,5…  )          (10…  )  
  lea…                                                                          
  obl…                                                                          
  Net                                                                           
  cash                                                                          
  used    $      (13,…  )    $     (13,…  )    $     (437…  )    $     (10…  )  
  in                                                                            
  fin…                                                                          
  act…                                                                          
  Net                                                                           
  inc…                                                                          
  in                                                                            
  cash           167,…             71,0…             629,…             80,…     
  and                                                                           
  cash                                                                          
  equ…                                                                          
  Cash                                                                          
  and                                                                           
  cash                                                                          
  equ…           550,…             70,2…             88,4…             61,…     
  at                                                                            
  beg…                                                                          
  of                                                                            
  per…                                                                          
  Cash                                                                          
  and                                                                           
  cash                                                                          
  equ…    $      717,…       $     141,…       $     717,…       $     141…     
  at                                                                            
  end                                                                           
  of                                                                            
  per…                                                                          
  Cash                                                                          
  and                                                                           
  cash                                                                          
  equ…                                                                          
  inc…                                                                          
  in                                                                            
  ass…               —               956                 —              956     
  held                                                                          
  for                                                                           
  sale                                                                          
  at                                                                            
  end                                                                           
  of                                                                            
  per…                                                                          
  Cash                                                                          
  and                                                                           
  cash                                                                          
  equ…                                                                          
  inc…                                                                          
  in      $      717,…       $     140,…       $     717,…       $     140…     
  con…                                                                          
  ope…                                                                          
  at                                                                            
  end                                                                           
  of                                                                            
  per…                                                                          
                                                                                
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Segment
EBITDA For the three and nine months ended September 30, 2026 and 2025
(Unaudited) The following table reconciles net income from continuing operations
to Segment EBITDA:
                                                                                
                                               For                              
           For the                             the                              
           Three                               Nine                             
           Months                              Months                           
  ($ in    Ended    Septe…                     Ended   Septem…                  
  thou…    2026        30,    2025             2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  inco…                                                                         
  from     $        100,8…    $      37,488    $       261,689    $     55,245  
  cont…                                                                         
  oper…                                                                         
  Segm…                                                                         
  depr…             30,794           33,791             97,367          102,2…  
  and                                                                           
  amor…                                                                         
  Expe…                                                                         
  not                                                                           
  allo…                                                                         
  at                                                                            
  segm…                                                                         
  leve…                                                                         
  Sell…                                                                         
  gene…                                                                         
  and               82,080           73,060            239,681          239,0…  
  admi…                                                                         
  expe…                                                                         
  Depr…                                                                         
  and                7,578            6,962             21,522          21,149  
  amor…                                                                         
  Inte…                                                                         
  expe…             31,038           38,235            106,532          118,7…  
  net                                                                           
  Inco…                                                                         
  tax               28,640           12,120             44,099          13,118  
  expe…                                                                         
  Total                                                                         
  Segm…    $        280,9…    $     201,656    $       770,890    $     549,6…  
  EBIT…                                                                         
                                                                                
BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of EBITDA and
Adjusted EBITDA For the three and nine months ended September 30, 2026 and 2025
(Unaudited) The following table reconciles net income from continuing operations
to EBITDA and Adjusted EBITDA:
                                                                                
                                               For                              
           For the                             the                              
           Three                               Nine                             
           Months                              Months                           
  ($ in    Ended    Septe…                     Ended   Septem…                  
  thou…    2026        30,    2025             2026        30,    2025          
 ────────────────────────────────────────────────────────────────────────────── 
  Net                                                                           
  inco…                                                                         
  from     $        100,8…    $      37,488    $       261,689    $     55,245  
  cont…                                                                         
  oper…                                                                         
  Inco…                                                                         
  tax               28,640           12,120             44,099          13,118  
  expe…                                                                         
  Inte…                                                                         
  expe…             31,038           38,235            106,532          118,7…  
  net                                                                           
  Depr…                                                                         
  and               38,372           40,753            118,889          123,4…  
  amor…                                                                         
  EBIT…    $        198,8…    $     128,596    $       531,209    $     310,5…  
  Non-…                                                                         
  shar…             17,871           14,173             50,475          46,155  
  comp…                                                                         
  (1)                                                                           
  Acqu…                                                                         
  inte…                                                                         
  and                2,855            5,462             15,585          34,811  
  tran…                                                                         
  costs                                                                         
  (2)                                                                           
  Rest…                                                                         
  and                                                                           
  dive…                                                                         
  and                8,181           12,212             25,756          42,493  
  other                                                                         
  costs                                                                         
  (3)                                                                           
  Total    $        28,907    $      31,847    $        91,816    $     123,4…  
  adju…                                                                         
  Adju…    $        227,7…    $     160,443    $       623,025    $     434,0…  
  EBIT…                                                                         
                                                                                
(1) Represents non-cash share-based compensation to certain members of our
management and full-time employees. (2) Represents transaction costs incurred in
connection with planned, completed, or terminated acquisitions, which include
investment banking fees, legal diligence and related documentation costs,
finance and accounting diligence and documentation; costs associated with the
integration of acquisitions, including any facility consolidation, integration
travel, or severance; and costs associated with other planned, completed, or
terminated non-routine transactions. (3) Represents costs associated with
restructuring-related activities, including closure, and related license
impairment, and severance expenses associated with certain enterprise-wide or
significant business line cost-savings measures.

BrightSpring Health Services, Inc. and Subsidiaries Reconciliation of Adjusted
EPS For the three and nine months ended September 30, 2026 and 2025 (Unaudited)
The following table reconciles diluted EPS to Adjusted EPS:
                                                                                
          For                                  For                              
          the                                  the                              
          Three                                Nine                             
  (sh…    Mont…                                Mon…                             
  in      Ended  Sept…                         End…  Sept…                      
  tho…    2026     30,       2025              2026    30,       2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Dil…    $       0.46       $      0.17       $      1.18       $     0.26     
  EPS                                                                           
  Non…                                                                          
  sha…            0.08              0.07              0.23             0.21     
  com…                                                                          
  (1)                                                                           
  Acq…                                                                          
  int…                                                                          
  and             0.01              0.03              0.07             0.16     
  tra…                                                                          
  cos…                                                                          
  (1)                                                                           
  Res…                                                                          
  and                                                                           
  div…                                                                          
  and             0.04              0.06              0.12             0.19     
  oth…                                                                          
  cos…                                                                          
  (1)                                                                           
  Inc…                                                                          
  tax                                                                           
  imp…           (0.05  )          (0.03  )          (0.23  )          (0.…  )  
  on                                                                            
  adj…                                                                          
  (2)                                                                           
  Adj…    $       0.54       $      0.30       $      1.37       $     0.69     
  EPS                                                                           
  Wei…                                                                          
  ave…                                                                          
  com…                                                                          
  sha…                                                                          
  out…                                                                          
  used                                                                          
  in                                                                            
  cal…           220,…             217,…             220,…             218…     
  dil…                                                                          
  U.S.                                                                          
  GAAP                                                                          
  net                                                                           
  inc…                                                                          
  per                                                                           
  sha…                                                                          
  Wei…                                                                          
  ave…                                                                          
  com…                                                                          
  sha…                                                                          
  out…                                                                          
  used                                                                          
  in             220,…             217,…             220,…             218…     
  cal…                                                                          
  dil…                                                                          
  Non…                                                                          
  inc…                                                                          
  per                                                                           
  sha…                                                                          
                                                                                
(1) This adjustment reflects the per share impact of the adjustment reflected
within the definition of Adjusted EBITDA. (2) The income tax impact of non-GAAP
adjustments is calculated using the estimated tax rate for the respective non-
GAAP adjustment. For all periods presented, the income tax impact on adjustments
is inclusive of a discrete tax benefit related to share-based compensation.

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BTSG/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.